GlassScriptPhysician profile
Ann M Scanlon-Smith
NPI 1609817899
$2,083.99
in general payments reported to CMS, 2019-2025
8 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $93.92 · 2023: $713 · 2024: $449 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,529.87 | 2021-2025 | Biktarvy, Yeztugo |
| Viiv Healthcare Company | $271.06 | 2022-2024 | Cabenuva, Dovato |
| Janssen Products, LP | $115.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.82 | 2024 | Delstrigo, Pifeltro, Dificid |
| Boston Scientific Corporation | $39.97 | 2025 | Enroute Transcarotid Neuroprotection System |
| Mannkind Corporation | $22.17 | 2024 | |
| Janssen Biotech, INC. | $16.17 | 2023 | Symtuza |
| Abbvie INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Scanlon-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.